AST SpaceMobile Gears Up for BlueBird Satellite Launch on June 17

T. Harv Eker

Author of "Secrets of the Millionaire Mind," focusing on the mindset and psychology of wealth.

AST SpaceMobile, a pioneering force in satellite communications, is poised to elevate its global cellular broadband capabilities with the scheduled launch of its latest BlueBird satellites. These advanced units are engineered to deliver a substantial upgrade in data speed, promising a more robust and expansive direct-to-device network for subscribers worldwide. This development underscores the company's continuous efforts to innovate and scale its space-based infrastructure.

The upcoming launch on June 17 will see BlueBird 8, 9, and 10 satellites propelled into orbit from Cape Canaveral, Florida, atop a SpaceX Falcon 9 rocket. This event marks a critical juncture for AST SpaceMobile, as these new satellites are designed to offer nearly twice the peak data speeds compared to the initial Block 1 BlueBird satellites. The previous generation already demonstrated impressive performance, achieving download speeds of 98.9 Mbps on standard smartphones, a testament to the company's technological prowess.

Scott Wisniewski, President of AST SpaceMobile, highlighted the significance of this deployment, emphasizing it as another stride towards building and expanding a truly global space-based cellular broadband network. This strategic expansion is vital for connecting underserved regions and enhancing mobile communication accessibility across the globe.

In the financial markets, shares of AST SpaceMobile (NASDAQ: ASTS) observed a modest dip of over 2% on Tuesday, reflecting a broader cooling trend among high-beta growth stocks amidst a risk-off trading environment. Major indices like the Nasdaq Composite and S&P 500 also experienced declines, falling by 2.01% and 0.84% respectively. Despite this short-term fluctuation, the company's stock has maintained an upward trajectory over the longer term, boasting an impressive 155.03% increase in value over the past year.

However, recent indicators suggest a moderation in immediate market momentum. The stock is currently trading below its 20-day and 100-day simple moving averages, signaling a period of consolidation after reaching its swing and 52-week highs in May. Nevertheless, the long-term outlook remains positive, with the stock positioned above its 200-day simple moving average and slightly above its 50-day average. The "golden cross" formation from June 2025, where the 50-day moving average surpassed the 200-day average, continues to hold, suggesting underlying strength. Investors are closely monitoring whether the shares can maintain support near the 50-day average.

Momentum analysis further reinforces the idea of a temporary cool-down rather than a significant reversal. The stock's relative strength index (RSI) stands at 47.26, indicating a neutral market sentiment where neither buying nor selling pressures dominate. Key resistance is identified around $104.00, aligning with the 20-day moving average, while strong support is observed near $73.50, a level that has historically attracted buyer interest.

AST SpaceMobile has forged strategic alliances with nearly 60 mobile network operators globally, collectively serving over 3 billion subscribers. These collaborations include prominent industry players such as AT&T Inc. (NYSE: T), Verizon Communications Inc. (NYSE: VZ), Vodafone Group Plc (NASDAQ: VOD), and Alphabet Inc. (NASDAQ: GOOGL). These partnerships are crucial for integrating AST SpaceMobile's innovative space-based network with existing mobile infrastructures, expanding reach and enhancing service delivery. The precise timing of the satellite launch remains contingent on prevailing weather conditions and operational readiness.

you may like

youmaylikeicon
Rivian Stock Experiences Decline Amid Macroeconomic Headwinds

Rivian Stock Experiences Decline Amid Macroeconomic Headwinds

By Vicki Robin
Incyte Invests $1.25 Billion in Breakthrough Bleeding Disorder Treatment

Incyte Invests $1.25 Billion in Breakthrough Bleeding Disorder Treatment

By Dave Ramsey
Oracle's Strong Q4 Forecast: A Look at Revenue Projections and Market Sentiment

Oracle's Strong Q4 Forecast: A Look at Revenue Projections and Market Sentiment

By Dave Ramsey
AstraZeneca's GLP-1 Oral Drug Advances to Phase 3 for Weight Management and Diabetes

AstraZeneca's GLP-1 Oral Drug Advances to Phase 3 for Weight Management and Diabetes

By Scott Pape
Novanta's Strategic Acquisition of Riverpoint Medical to Enhance Minimally Invasive Surgery Portfolio

Novanta's Strategic Acquisition of Riverpoint Medical to Enhance Minimally Invasive Surgery Portfolio

By Natalie Pace
Apple's Strategic Retail Adjustments Amidst Evolving Mall Landscape

Apple's Strategic Retail Adjustments Amidst Evolving Mall Landscape

By Bola Sokunbi
Infrastructure: The Linchpin for Institutional Digital Asset Adoption

Infrastructure: The Linchpin for Institutional Digital Asset Adoption

By Vicki Robin
Verizon: A Safe Bet in a Volatile Market?

Verizon: A Safe Bet in a Volatile Market?

By JL Collins
Oil Market Dynamics: Ceasefire's Impact and Global Demand Shifts

Oil Market Dynamics: Ceasefire's Impact and Global Demand Shifts

By Bola Sokunbi
Analyzing Investment Potential: RPM International Inc. Stock Evaluation

Analyzing Investment Potential: RPM International Inc. Stock Evaluation

By JL Collins
Uber Harnesses Driver Downtime to Fuel AI Data Production

Uber Harnesses Driver Downtime to Fuel AI Data Production

By T. Harv Eker
Iron Mountain's Investment Potential: A Deep Dive into its Growth and Stability

Iron Mountain's Investment Potential: A Deep Dive into its Growth and Stability

By T. Harv Eker
Louisiana-Pacific Corporation: An Attractive Investment Opportunity?

Louisiana-Pacific Corporation: An Attractive Investment Opportunity?

By JL Collins
EU Mandates Meta to Open WhatsApp to Rival AI Chatbots

EU Mandates Meta to Open WhatsApp to Rival AI Chatbots

By Mr. Money Mustache
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

By JL Collins